Conduit Therapeutics - Aset Bersih saben Siji Saham CDT

The stability of Conduit Pharmaceuticals (CDT) is confirmed by its adherence to bioethics and ESG standards in research, which supports the expected book value per share. The operational base relies on purchasing ready-made solutions from industry behemoths to expand into neurology and the autoimmune sector. Growth is driven by its role as an incubator for bringing kidney and joint medications to market. Meanwhile, 4043.69 represents the current value of the indicator.

Nilai Akuntansi Saham: Conduit Pharmaceuticals Inc (CDT) kanggo 21.02.2024 - 27.10.2026

conduitpharma.com - rincian analitis lan metrik utama (CDT)

- rega lan prakiraan konsensus rega:

Kutipan saham Conduit Pharma|CDT - Rega prakiraan analis

- data kapitalisasi pasar:

Nilai pasar Conduit Pharmaceuticals Inc.|CDT - Nilai Wutuh Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham Conduit Pharmaceuticals|CDT - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku conduitpharma.com|CDT - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Conduit Pharmaceuticals|CDT - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Conduit Pharmaceuticals Inc.|CDT - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Conduit Pharmaceuticals Inc.

Analisis kabeh metrik perusahaan:Conduit Pharma (CDT)

Produk mawa merek Conduit Pharmaceuticals Inc.

The scale of Conduit Pharmaceuticals (CDT) operations relies on tangible assets, and the change in the book value per share reflects the residual value of equity minus all liabilities. This metric determines the intrinsic value of the business, which remains stable for the biomedical sector due to the humanitarian status of its products and the minimal impact of geopolitical risks on the stability of the company's financial foundation.

Analisis pesaing